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Maternal mortality in Brazil is a major problem.It is about 10 times that of Canada or England.What do these three countries have in common
regarding maternal mortality? Hypertension in pregnancy,
a major cause of maternal death in developed and
developing countries. Among the hypertensive
complications of pregnancy, pre-eclampsia and eclampsia
are of utmost importance when considering any strategy
of maternal death prevention.
A very important issue is the treatment of convulsions
in eclampsia. Since the first report of the use of magnesium
sulfate in 1906, many other new drugs have been developed
and there have been different opinions regarding which
the best treatment would be. After 60 years of 'experience'
and opinions, preference has been distributed among
different types of drugs.
In the US, the large majority of doctors believed the
best treatment of fits was magnesium sulfate. About 98%
of the British doctors and many of their colleagues of the
Commonwealth preferred diazepam or phenitoin.
Brazilian doctors, being mostly influenced by
American medicine, preferred magnesium sulfate;
however, diazepam and phenitoin were still considerably
used because of the simultaneous influence of British
medicine.
The treatment of any severe disease as eclampsia
requires a high degree of certainty, whenever possible. A
systematic review of literature up to one year ago would
result in complete uncertainty as to the best treatment.
The "Collaborati ve Eclampsia Trial Group Report"
of June this year (I) brought the necessary light to this
important subject.
Designed as a multicenter collaborati ve control trial
by Dr. Lilia Duley from the University of Oxford, the trial
received strong support from South American, African,
and Indian researchers. 1,687 patients were randomized
and treated in two trial branches: magnesium sulfate versus
diazepam (S. America) and magnesium sulfate versus
phenitoin (Africa and India). The results showed that the
recurrence of fits in the magnesium sulfate groups was
52% less than in the diazepam group and 67% less than in
the phenitoin-treated groups respectively.
Besides, the study of secondary outcomes suggest
important reductions of maternal/fetal morbidity in the
patients treated with magnesium sulfate. The authors
concluded, based on strong evidence, that magnesium
sulfate is the drug of choice for the treatment of convulsions
in the patients with eclampsia. These important results led
to the establishment, by WHO's Maternal Mortality
Committee experts, of the Eclampsia Day, to be observed
every June 12.
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The "Collaborative Eclampsia Trial," which can be
considered the most important clinical trial in Obstetrics
of this century, was conducted successfully thanks to an
association between researchers in a developed country
(Oxford University, in the UK) and well-trained
researchers in developing countries, where the frequency
of maternal complications and deaths is high. The
conclusions of this study are useful for all mankind.
There are many other health problems in other areas
suitable for applying the "Eclampsia Trial Collaborative
Group" study as a model, where the combination of
goodwill, expertise, and frequency of outcomes will be
integrated to bring light where there is only the heat of
medical controversy.
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